Psychopharmacology

Liraglutide improves depression and thinking problems in obese rats by affecting brain cell recycling and growth pathways

Updated

Abstract

Chronic liraglutide treatment (300 µg/kg/day for 28 days) significantly improved depressive-like behaviors and cognitive deficits in high-fat diet rats.

  • Liraglutide administration was associated with increased levels of brain-derived neurotrophic factor (BDNF) in the hippocampus.
  • Enhanced activation of the PI3K/Akt/mTOR signaling pathway was observed following liraglutide treatment.
  • The treatment resulted in reduced expression of autophagic markers Beclin-1 and LC3, as well as inflammatory markers TNF-α and IL-6.
  • HFD-induced neurodegeneration in the hippocampus was ameliorated by chronic liraglutide treatment.

Simplified

Key numbers

< 0.0001
Increase in
Significant increase in in the group vs. group.
< 0.01
Decrease in Immobility Time
Significant decrease in immobility time in the / group vs. group.
< 0.0001
Increase in BDNF Levels
Significant increase in BDNF levels in the / group vs. group.

Key figures

Fig. 1
Timeline of and treatment with behavioral tests in rats
Anchors the study design by outlining diet, treatment, and behavioral testing timing in the rat model
213_2025_6834_Fig1_HTML
  • Panel A
    Experimental timeline showing 11 weeks of high-fat diet (HFD) followed by 1 week of liraglutide (Lira) treatment at 300 µg/kg/day during week 12
  • Panel A
    Behavioral tests performed during liraglutide treatment week include (), (SPT), (OFT), and (FST)
  • Panel A
    Sacrifice of animals occurs after completion of behavioral tests on day 84
Fig. 2
Behavioral and body weight changes in (HFD) rats treated with versus controls
Highlights liraglutide’s ability to reduce weight gain and improve depressive and cognitive behaviors in HFD rats
213_2025_6834_Fig2_HTML
  • Panel A
    Body weight change over 12 days; HFD group shows the largest increase, liraglutide treatment reduces weight gain in HFD rats
  • Panel B
    percentage; HFD rats show reduced preference, liraglutide treatment increases preference in HFD rats
  • Panel C
    immobility time; HFD rats have higher immobility, liraglutide reduces immobility in HFD rats
  • Panel D
    Number of crossed squares in ; HFD rats cross fewer squares, liraglutide increases crossings in HFD rats
  • Panel E
    Frequency of rearing in open field test; no visible difference between groups
  • Panel F
    Time spent in the center zone (CZ) of open field; HFD rats spend more time, liraglutide reduces time in HFD rats
  • Panel G
    Frequency of entering the center zone; HFD rats enter less, liraglutide increases entries in HFD rats
  • Panel H
    Latency to leave the center zone; HFD rats have longer latency, liraglutide reduces latency in HFD rats
  • Panel I
    Time to reach the hidden platform in over 5 days; HFD rats take longer, liraglutide reduces latency in HFD rats
  • Panel J
    Time spent in target quadrant in Morris water maze; HFD rats spend less time, liraglutide increases time in HFD rats
Fig. 3
Gene expression levels of , , , , and in hippocampus of -exposed rats treated with saline or
Highlights liraglutide’s association with increased PI3K/Akt/mTOR and reduced markers in HFD rat hippocampus
213_2025_6834_Fig3_HTML
  • Panel A
    Hippocampal PI3K gene expression is lower in HFD saline rats versus no HFD saline, and appears higher in HFD liraglutide rats compared to HFD saline
  • Panel B
    Hippocampal Akt gene expression is reduced in HFD saline rats versus no HFD saline, and is visibly increased in HFD liraglutide rats compared to HFD saline
  • Panel C
    Hippocampal mTOR gene expression is lower in HFD saline rats versus no HFD saline, and appears higher in HFD liraglutide rats compared to HFD saline
  • Panel D
    Hippocampal Beclin 1 gene expression is higher in HFD saline rats versus no HFD saline, and appears reduced in HFD liraglutide rats compared to HFD saline
  • Panel E
    Hippocampal LC3 gene expression is increased in HFD saline rats versus no HFD saline, and appears lower in HFD liraglutide rats compared to HFD saline
Fig. 5
Hippocampal tissue structure in control, , , and HFD/Lira rat groups
Highlights reduced hippocampal layer thickness and neuronal degeneration in HFD rats partially improved by liraglutide treatment
213_2025_6834_Fig5_HTML
  • Panels A-C
    Control group hippocampus with normal molecular (green arrows), pyramidal (red arrows), and polymorphic (blue arrows) layers
  • Panels D-E
    Lira group hippocampus showing normal structure and neurons with large cell bodies and pale euchromatic nuclei in (green arrows)
  • Panels F-H
    HFD group hippocampus with reduced thickness of pyramidal (red arrows) and polymorphic (blue arrows) layers, neuronal degeneration, irregular (blue arrows), and dilated congested blood vessels (red arrows)
  • Panels I-J
    HFD/Lira group hippocampus with reduced pyramidal layer thickness (red arrows), some normal neurons (green arrows), and some degenerated neurons (green arrows)
1 / 4

Full Text

What this is

  • This research investigates the effects of liraglutide on depressive and cognitive deficits in rats fed a high-fat diet (HFD).
  • The study focuses on the role of the PI3K/Akt/mTOR signaling pathway and in the brain.
  • Findings indicate that liraglutide not only aids in weight management but also addresses obesity-related psychiatric disorders.

Essence

  • Liraglutide treatment improves depressive-like behaviors and cognitive deficits in HFD-exposed rats by enhancing hippocampal PI3K/Akt/mTOR signaling and modulating .

Key takeaways

  • Chronic liraglutide administration significantly reduced depressive-like behaviors in HFD rats, as evidenced by improved performance in the sucrose preference and forced swimming tests.
  • Liraglutide treatment also enhanced cognitive function in HFD rats, reflected by improved performance in the Morris water maze test.
  • The treatment increased the expression of neuroprotective factors like BDNF and improved PI3K/Akt/mTOR signaling while reducing markers of inflammation and .

Caveats

  • The study lacks experiments with GLP-1 receptor antagonists to confirm liraglutide's receptor specificity.
  • The relatively young age of the rats and absence of certain measurements limit the interpretation of autophagic flux.

Definitions

  • autophagy: A cellular process that degrades and recycles damaged organelles and proteins to maintain homeostasis.
  • PI3K/Akt/mTOR pathway: A signaling pathway that regulates cell growth, metabolism, and autophagy, often implicated in neurodegenerative diseases.

Simplified

Funding

Competing interests

Declarations. Ethical approval: The study was conducted in accordance with EU Directive 2010/63/EU for animal experiments and was approved by the Research Ethics Committee of the Faculty of Medicine, Ain Shams University (FMASU-REC). FMASU-REC operates under Federal Wide Assurance. No. FWA 000017585 (approval number: FMASU R231/2022). Consent to participate: Not applicable. Consent to publish: Not applicable. Competing interests: On behalf of all authors, the corresponding author states that there is no conflict of interest. Conflict of interest: All authors declared that there is no conflict of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free